Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic.

Slides:

Advertisements

Similar presentations

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Advertisements

Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non– Small-Cell Lung Cancer Yen-Ting Lin, MD, Yu-Fen Wang, MD, James Chih-Hsin.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk Ping Yang, MD,

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

ALK FISH and IHC: You Cannot Have One without the Other

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Andreas Rimner, MD, Daniel R. Gomez, MD, Abraham J

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

Meghan Campo, MD, David Gerber, MD, Justin F. Gainor, MD, Rebecca S

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Masatsugu Hamaji,

Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic.

Frank Detterbeck, MD Journal of Thoracic Oncology

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

The Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung Cancer Justin F. Gainor, MD, Sai-Hong Ignatius Ou, MD, PhD, Jennifer.

Patterns of regional failure in stage III non-small cell lung cancer treated with neoadjuvant chemoradiation therapy and resection Shalini Garg, MD,

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases Tao.

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

P3.02b-125 Failure to Tyrosine Kinase Inhibitors and Patterns of Progression in Patients with Advanced Non-Small Cell Lung Cancer Feliciano Barron, Laura-Alejandra.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival after Stereotactic Body Radiation Therapy for Lung Cancer Nami.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis Bin-Chi Liao,

Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy Naomi E. Verstegen,

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Heidi B. Rolke, Frode Gallefoss Journal of Thoracic Oncology

Mitotic Inhibitors Journal of Thoracic Oncology

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Proton SBRT for Medically Inoperable Stage I NSCLC

MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation Ling Huang, MS, She-Juan An, PhD, Zhi-Hong.

Stereotactic Body Radiation Therapy for Primary Lung Cancers >3 Centimeters John J. Cuaron, MD, Ellen D. Yorke, PhD, Amanda Foster, BA, Meier Hsu, MS,

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Iris Metastasis from Small-Cell Lung Cancer

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next- Generation Sequencing and Successfully Treated with a MET Inhibitor Carrie.

Phase I Study of Lenalidomide in Solid Tumors

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Gaurav Marwaha, MD, Kevin L. Stephans, MD, Neil M

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?

Manoj P. Menon, MD, MPH, Keith D. Eaton, MD, PhD

Genetic Changes in Squamous Cell Lung Cancer: A Review

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

International Thymic Malignancies Interest Group: A Way Forward

European Lung Cancer Conference (ELCC) 2016 Organisation

Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer Elena Bolzacchini, MD,

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

Management of Mediastinal Relapse after Treatment with Stereotactic Body Radiotherapy or Accelerated Hypofractionated Radiotherapy for Stage I/II Non–Small-

Todd J. Carpenter, MD, Kenneth E. Rosenzweig, MD

IASLC 6th Latin American Conference on Lung Cancer

Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small- Cell Lung Cancer Jih-Hsiang Lee, MD, Yu-Lin Lin, MD, Wei-Hsun Hsu,

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery Raja M. Flores, MD The Journal.

Liseth L. van den Berg, MD, Theo J. Klinkenberg, MD, Harry J. M

Epidemiology of Thymoma and Associated Malignancies

Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping Ibiayi Dagogo-Jack, MD, Justin.

The Current Role of Whole Brain Radiation Therapy in Non–Small Cell Lung Cancer Patients Gokoulakrichenane Loganadane, MD, Lizza Hendriks, MD, PhD, Cécile.

Long-Term Follow-Up of a Phase I/II Trial of Dose Escalating Three-Dimensional Conformal Thoracic Radiation Therapy with Induction and Concurrent Carboplatin.

Presentation transcript:

Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy Hani Al-Halabi, MD, Karl Sayegh, MD, Subba R. Digamurthy, MD, Andrzej Niemierko, PhD, Zofia Piotrowska, MD, MPH, Henning Willers, MD, Lecia V. Sequist, MD, MPH Journal of Thoracic Oncology Volume 10, Issue 11, Pages 1601-1607 (November 2015) DOI: 10.1097/JTO.0000000000000648 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Pattern of failure analysis. A, The cumulative incidence of any progression and each of the three patterns of failure, original site failure (OF), distant site failure (DF), and simultaneous OF/DF (ODF) as a function of follow-up time. B, Estimated probability of each failure type (OF, DF, ODF) as a function of primary tumor size. Journal of Thoracic Oncology 2015 10, 1601-1607DOI: (10.1097/JTO.0000000000000648) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions